RBC lists antibody-drug conjugates (ADCs) as $30 billion category by 2030
Share

RBC lists antibody-drug conjugates (ADCs) as $30 billion category by 2030

CNBC's Angelica Peebles reports on opportunities in the pharmaceutical sector.
02:45
Mon, Oct 23 202312:05 PM EDT